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Abstract
Pain is necessary to alert us to actual or potential tissue damage. Specialized nerve cells in
the body periphery, so called nociceptors, are fundamental to mediate pain perception and
humans without pain perception are at permanent risk for injuries, burns and mutilations.
Pain insensitivity can be caused by sensory neurodegeneration which is a hallmark of
hereditary sensory and autonomic neuropathies (HSANs). Although mutations in several
genes were previously associated with sensory neurodegeneration, the etiology of many
cases remains unknown. Using next generation sequencing in patients with congenital loss
of pain perception, we here identify bi-allelic mutations in the FLVCR1 (Feline Leukemia
Virus subgroup C Receptor 1) gene, which encodes a broadly expressed heme exporter.
Different FLVCR1 isoforms control the size of the cytosolic heme pool required to sustain
metabolic activity of different cell types. Mutations in FLVCR1 have previously been linked
to vision impairment and posterior column ataxia in humans, but not to HSAN. Using fibro-
blasts and lymphoblastoid cell lines from patients with sensory neurodegeneration, we here
show that the FLVCR1-mutations reduce heme export activity, enhance oxidative stress
and increase sensitivity to programmed cell death. Our data link heme metabolism to sen-
sory neuron maintenance and suggest that intracellular heme overload causes early-onset
degeneration of pain-sensing neurons in humans.
Author Summary
Hereditary Sensory and Autonomic Neuropathy (HSAN) is a genetic disorder mainly
characterized by the impairment of sensory neurons, which transmit information about
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sensations such as pain, temperature and touch. Therefore, unintentional self-injury, lead-
ing to ulcers and eventually amputations are common in affected individuals. Although
mutations in several genes were previously associated with sensory neurodegeneration
and pain insensitivity, the etiology of many cases remains unknown. We here identify
mutations in the heme exporter protein FLVCR1 in patients with congenital inability to
experience pain. We showed that FLVCR1 mutations results in reduced heme export
activity, enhanced oxidative stress and increased sensitivity to programmed cell death.
These data assign a surprising role for heme to sensory neuron maintenance.
Introduction
Neurodegenerative disorders affecting peripheral sensory neurons lead to loss of pain percep-
tion as disease hallmark. The absence of protective behaviors towards noxious stimuli causes
unintentional self-injuries and chronic ulcerations. Soft tissue infections and osteomyelitis,
often requiring amputations, are common and complicate this disorder [1, 2]. Autonomic dys-
function and motor deficits may be additional features of sensory and autonomic neuropathies
(HSANs). Prominent loss of large and small myelinated fibers distinguishes sensory neuropa-
thies from clinically similarly presenting channelopathy-associated pain insensitivity (CIP)[3].
Proteins which are involved in sensory neurodegeneration affect distinct molecular path-
ways: sphingolipid-metabolism, membrane-shaping of organelles, regulation of ion channels,
endoplasmic reticulum turnover and axonal trafficking[1, 4–8]. However, the molecular
mechanisms underlying sensory neurodegeneration are still incompletely understood and dis-
ease-causing mutations remain to be identified in a substantial number of patients.
Rapid progress in next-generation sequencing (NGS) technology has transformed the field
of medical genomics leading to the identification of novel disease-genes[9, 10]. In this study,
next generation sequencing was performed in patients with HSAN but without mutations in
the known genes associated with the disorder. Causative mutations were found in FLVCR1
(Feline Leukemia Virus subgroup C Receptor 1), a gene that has previously been associated to
Posterior Column Ataxia and Retinitis Pigmentosa (PCARP)[11–16].
FLVCR1 is an ubiquitously expressed heme exporter[17, 18], member of the Major Facilita-
tor Superfamily (MFS) transporters[19]. Two different isoforms have been described.
FLVCR1a resides in the plasma membrane and is responsible for heme detoxification in sev-
eral cell types, such as erythroid progenitors, endothelial cells, hepatocytes, lymphocytes and
intestinal cells[18, 20–25]. FLVCR1b is located on mitochondria and is involved in the trans-
port of newly synthesized heme from mitochondria to the cytosol[18]. The expression of
FLVCR1a and FLVCR1b is needed to control the size of the cytoplasmic free-heme pool,
which is essential for proper metabolic functions[21, 23]. Heme is an essential co-factor
involved in multiple biological processes: oxygen transport and storage, electron transfer, drug
and steroid metabolism, signal transduction and microRNA processing[26]. However, excess
free-heme is highly toxic due to its ability to promote oxidative stress, proteasome inhibition
and mitochondrial dysfunction, that ultimately lead to cell death[26–28]. For this reason, the
intracellular free-heme pool is finely regulated at multiple levels[26] and FLVCR1a-mediated
heme export contributes to this process[21, 22, 26]. Our data show that primary fibroblasts
and lymphoblastoid cell lines from patients with sensory neurodegeneration have reduced
heme export activity due to FLVCR1-mutations. This results in enhanced oxidative stress and
increased sensitivity to programmed cell death. These data add heme metabolism to the molec-
ular pathways implicated in sensory neuron maintenance and pain processing.
FLVCR1 Mutations Cause Pain Insensitivity
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Results
Mutations in the FLVCR1 gene cause sensory neurodegeneration with
loss of pain perception in humans
We studied trios with an affected child and healthy parents with the diagnosis of hereditary
sensory and autonomic neuropathy (HSAN) (Fig 1 and Table 1). In an Italian boy with early-
onset pain insensitivity (patient 1) and non-consanguineous parents whole-exome sequencing
identified 559 variants with low prevalence (<0,01%) in dbSNP, the 1000-Genomes project,
the Exome Variant Server or the ExAC browser. Variants were prioritized for de novo muta-
tions and compound-heterozygous / homozygous variants (S1 Table). Amongst these variants
compound-heterozygosity for mutations in FLVCR1 (NM_014053.3) was detected (Fig 1B and
1C). The heterozygous mutation c.574T>C; p.(Cys192Arg) has been previously reported as
homozygous mutation in autosomal-recessive posterior column ataxia with retinitis pigmen-
tosa (PCARP)[14]. The respective cytosine is located in the third transmembrane domain of
the FLVCR1 protein (Fig 1B) and is evolutionarily conserved among species. The mother of
patient 1 is heterozygous carrier of the c.574T>C mutation. The second mutation was inher-
ited from the father and is a heterozygous frameshift-mutation c.610del; p.(Met204Cysfs56).
The deletion results in a premature stop codon, hence suggesting complete loss of protein
function. Both mutations were considered as likely pathogenic accordingly to in-silico predic-
tion programs (S2 Table). To forecast gene-specific pathogenicity of the variants in the context
of the FLVCR1 gene, a Mutation Significance Cutoff (MSC) 23.8 for CADD, 0.697 for Poly-
Phen2 and 0.04 for SIFT was applied based on calculations by the MSC server for HGMD and
ClinVar variants[29]. If applicable, all tools predicted a deleterious impact of the specific muta-
tions (S2 Table).
Patient 1 was the only child of non-consanguineous parents and at 23 months of age pre-
sented with severe psychomotor delay, no language acquisition, absent reaction to painful sti-
muli, ulcero-mutilations of mouth and hands, joint hypermobility and scoliosis. Sensory nerve
conduction was not evocable. The child had frequent crises resembling “dysautonomic crises”,
characterized by agitation and tachycardia, spontaneously resolving after vomiting or stool
emission. He had chronic macrocytic anemia, with normal ferritin, syderemia, transferrin,
vitamin B12 and folic acid levels; bone marrow examination showed hyporegenerative anemia.
At the age of 33 months he developed seizures. In the later disease course, optic atrophy and
retinal degeneration were also noticed (Table 1). The clinical presentation thus showed a pre-
dominant pain insensitivity phenotype with clinical symptoms partially overlapping with
PCARP, suggesting that distinct FLVCR1 mutations may result in different clinical outcomes.
To substantiate the role of FLVCR1 in sensory neuropathies additional index cases and
trios were subjected to next-generation sequencing using a gene panel consisting of 70 genes
implicated in HSAN and similar syndromes, including FLVCR1. Amongst 165 index cases, we
identified a second case with early-onset sensory neuropathy (patient 2) and compound het-
erozygous mutations c.661C>T; p.(Pro221Ser) and c.1324dup; p.(Tyr442Leufs7) in FLVCR1
(Fig 1B and 1D). The non-consanguineous family of European origin (mother, father, index
patient) was further subjected to trio exome-sequencing to evaluate mutations in other than
the initially tested genes. No other candidate gene which was likely to account for the clinical
phenotype was identified by this approach (S1 Table).
Pro221 is an evolutionarily highly conserved amino acid residue of FLVCR1 and its muta-
tion to serine is likely to interfere with FLVCR1 function. This missense exchange is extremely
rare and accordingly to the Exome Aggregation Consortium (ExAC) has been observed in 1 of
120,990 alleles. Pro221Ser is also predicted as pathogenic (S2 Table). Again, the second
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FLVCR1 allele harbors a loss-of-function frameshift mutation, which has not been described
until now.
Patient 2 had mild developmental delay and started to walk with support at age of 24
months with a broad base gait. Speech was also delayed with first words at 22 months. At 12
months of age a non-healing wound at the tip of the right thumb with nail dystrophy was
noticed. Despite local medication necrosis and acroosteolysis occurred. Similar lesions
appeared on the 2nd and 3rd right fingers and left thumb with loss of nails and resorption of
the underlying soft tissues. Wounds were slow healing, resulting in atrophic scarring. At exam-
ination, the patient presented hyperactive and clumsy, and showed marked reduction to pain-
ful stimuli. Affected fingers had stubby ends and nail dystrophy (Fig 1A). He had a positive
histamine axonal flare response, and electroneurography showed a severe sensory neuropathy.
Electroencephalogram and brain MRI gave normal results, while total spine MRI showed syr-
inx from T5 to T10, minor irregularities of the cervical central ependymal canal, and mild
hyperintensity of the posterior columns (S1 Fig). An electroretinogram, performed at 3 years,
showed reduced a-wave amplitude suggestive for initial retinal epithelium degeneration.
Together, these data link FLVCR1 mutations to early-onset complicated sensory neuropathy.
Fig 1. Mutations in the FLVCR1 gene cause Sensory Neuropathy. (A) Non-healing wound lesions with nail dystrophy in patient 2 as clinical feature of
sensory neuropathy caused by FLVCR1 mutations. (B) Structure of the FLVCR1a protein (plasma membrane isoform). FLVCR1a-specific part is depicted
in green. Mutations are indicated in the scheme, electropherograms with mutations and pedigrees are given for patient 1 (C) and patient 2 (D).
doi:10.1371/journal.pgen.1006461.g001
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FLVCR1 mutations impair plasma membrane heme export in patient-
derived cells
To investigate the functional consequences of FLVCR1 mutations, primary fibroblasts were
derived from patient 1 whereas lymphoblastoid cell lines (LCLs) were generated from patient
2. qRT-PCR analyses showed that FLVCR1 mutations result in a specific decrease of FLVCR1a
transcript whereas FLVCR1b mRNA levels were unaffected in both patients (Fig 2A and 2B
and S2 Fig). Interestingly, immunoprecipitation and western blotting indicated that FLVCR1a
is still expressed in patient fibroblasts and LCLs (Fig 2C and 2D). These data indicate that the
mutations did not completely abolish FLVCR1a expression. Therefore, we hypothesized that
the mutations could interfere with the heme export ability of FLVCR1, thus resulting in intra-
cellular heme accumulation. To address this issue, we analyzed the expression of proteins
involved in heme and iron metabolism. The expression of ALAS1 (δ-aminolevulinc acid
synthase 1), the rate-limiting enzyme in the heme biosynthetic pathway, was similar in patient
and control fibroblasts (Fig 2E and 2G). However, increased expression of the heme degrading
enzyme HO1 (Heme oxygenase 1) was observed in patient compared to control fibroblasts
(Fig 2E and 2G). HO1 catalyzes the degradation of heme into biliverdin, carbon monoxide
and iron[30]. Consistent with the induction of HO1 in patient fibroblasts, increased mRNA
levels of the iron exporter FPN (Ferroportin) and the iron-storage proteins FT-L (Ferritin L)
and FT-H (Ferritin H) were observed in patient compared to control fibroblasts (Fig 2E). Con-
trary, patient LCLs were characterized by decreased ALAS1 and similar HO1 expression levels
compared to healthy donors (Fig 2F, 2H and S3 Fig). Consistent with reduced ALAS1 expres-
sion, we observed a slight decrease of FPN, FT-L and FT-H mRNA levels in patient compared
to control LCLs (Fig 2F).
To definitively demonstrate that FLVCR1 mutations impair plasma membrane export, the
amount of intracellular heme concentration was determined. Heme content was comparable
Table 1.
Feature Patient 1 Patient 2
Age at examination 33 months 41 months
Sex Male Male
Consanguinity - -
Compound heterozygous FLVCR1 mutations c.574T>C; p.(Cys192Arg), c.661C>T; p.(Pro221Ser),
c.610del; p.(Met204Cysfs*56) c.1324dup; p.(Tyr442Leufs*7)
Sensory neuropathy + +
Finger mutilations + +
Slow-healing ulcers/wounds + +
Osteomyelitis - -
Autonomic features Autonomic “crises”, tearing dysfunction -
Developmental delay + (severe) + (mild/moderate)
Ataxic gait NE +
Retinal involvement +/- +/-
Hepatic involvement + -
Bone marrow involvement Hyporegenerative anemia -
Hyperintensity of the posterior columns NE +
Syringomyelia - +
Brain atrophy + -
White matter anomalies + -
doi:10.1371/journal.pgen.1006461.t001
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Fig 2. FLVCR1 mutations impair heme export in patient-derived cells. (A) qRT-PCR analysis of FLVCR1a mRNA in patient 1
compared to control fibroblasts (black). Values represent mean ± SEM. n = 6. * = P<0.05. (B) qRT-PCR analysis of FLVCR1a mRNA in
patient 2 compared to control LCLs (grey). Values represent mean FLVCR1a mRNA levels in patient 2 compared to the mean FLVCR1a
FLVCR1 Mutations Cause Pain Insensitivity
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between patient and control fibroblasts (Fig 2I) and LCLs (Fig 2J) under resting conditions,
likely due to the induction of HO1 in patient fibroblasts and the reduction of ALAS1 in patient
LCLs (Fig 2E–2H). However, following the stimulation of heme synthesis with ALA (δ-amino-
levulinic acid), heme accumulation was observed in patient compared to control fibroblasts
(Fig 2I). Moreover, heme content was higher in patient LCLs compared to the mean heme
content of 4 different healthy donors LCLs (Fig 2J). Taken together these data indicate that
FLVCR1 mutations impair plasma membrane heme export resulting in a transient accumula-
tion of heme that activates cell-specific detoxifying mechanisms: excess-heme is rapidly catab-
olized by HO1 in patient-derived fibroblasts while heme downregulates its own synthesis in
patient-derived LCLs.
FLVCR1 mutations induce oxidative stress and enhance the sensitivity
to programmed cell death in patient-derived cells
Excess free-heme is highly toxic due to its ability to promote oxidative stress and lipid peroxi-
dation, leading to membrane injury and, ultimately, apoptosis[26]. To evaluate whether
FLVCR1 mutations influence cellular oxidative status, the expression of genes involved in the
antioxidant response was analyzed. Patient fibroblasts were characterized by decreased super-
oxide dismutase 1 (SOD1) and catalase mRNA levels, and increased superoxide dismutase 2
(SOD2) and thioredoxin transcripts (Fig 3A). Increased reactive oxygen species (ROS) were
observed in patient compared to control fibroblasts (Fig 3B). Moreover, ROS levels were
higher in patient LCLs compared to the mean ROS levels of 4 different healthy donors LCLs
(Fig 3C).
In order to investigate whether loss of FLVCR1a affects cell viability, the survival of cells
was evaluated by Annexin V staining. The percentage of Annexin V-positive cells was compa-
rable between patient and control fibroblasts under resting conditions (Fig 3D). However, fol-
lowing the stimulation with ALA, increased percentage of Annexin V-positive cells was
detected in patient compared to control fibroblasts (Fig 3D). In addition, following ALA treat-
ment, the percentage of Annexin V-positive cells was higher in patient LCLs compared to the
mean of 4 different healthy donors LCLs (Fig 3E). The same result was observed following the
stimulation of patient and controls LCLs with H2O2 (S4 Fig). In order to demonstrate that
increased apoptosis in patient cells treated with ALA was due to heme overload, we performed
rescue experiments by reducing intracellular heme loading. It has been previously reported
that Hemopexin (HX) facilitates heme export through FLVCR1[31, 32]. Thus, we added HX to
the medium. HX treatment ameliorate cell survival in patient LCLs treated with ALA in a dose
dependent manner (Fig 3F), thus suggesting that heme overload is responsible for the observed
phenotype.
mRNA levels of 4 different control LCLs. (C) Immunoprecipitation and western blotting of FLVCR1a in patient 1 compared to control
fibroblasts. A representative blot is shown. The antibody against SUMO was used as control. (D) Immunoprecipitation and western
blotting of FLVCR1a in patient 2 compared to control LCLs. A representative blot is shown. The antibody against SUMO was used as
control. (E) qRT-PCR analysis of ALAS1, HO1, FT-L, FT-H and FPN1 mRNA in patient compared to control fibroblasts. Values
represent mean ± SEM. n = 6. * = P<0.05; *** = P<0.001. (F) qRT-PCR analysis of ALAS1, HO1, FT-L, FT-H and FPN1 mRNA in
patient compared to control LCLs. Values represent mean mRNA levels in patient 2 compared to the mean mRNA levels of 4 different
control LCLs. (G) Western blot analysis of HO1 and ALAS1 protein in patient 1 compared to control fibroblasts. A representative blot is
shown. (H) Western blot analysis of ALAS1 and HO1 protein levels in patient 2 compared to 4 different control LCLs. A representative
blot is shown. (I) Measurement of heme content in patient 1 compared to control fibroblasts. Values represent mean ± SEM. n = 6. Two-
way ANOVA. *** = P<0.001. (J) Measurement of heme content in patient 1 compared to control LCLs. Values represent heme content
of patient 2 LCLs compared to the mean heme content of 4 different control LCLs. P1 = patient 1, P2 = patient 2, C = control.
doi:10.1371/journal.pgen.1006461.g002
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Fig 3. FLVCR1 mutations induce oxidative stress and increase the sensitivity to programmed cell death in patient-derived cells. (A)
qRT-PCR analysis of SOD1, SOD2, CATALASE and THIOREDOXIN1 mRNAs in patient 1 compared to control fibroblasts. Values represent
mean ± SEM. n = 3. * = P<0.05; ** = P<0.005; *** = P<0.001. (B) Measurement of ROS levels in patient 1 compared to control fibroblasts.
Values represent mean ± SEM. n = 6. ** = P<0.005. (C) Measurement of ROS levels in patient 2 compared to control LCLs. Values represent
ROS levels of patient 2 LCLs compared to the mean heme content of 4 different control LCLs. (D) Percentage of Annexin V-positive cells in
patient 1 compared to control fibroblasts, under basal conditions and following the stimulation with 5mM ALA for 72 hours. Values represent
FLVCR1 Mutations Cause Pain Insensitivity
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Taken together these data indicate that the impairment of FLVCR1-mediated heme export
triggers oxidative stress and increases the susceptibility to programmed cell death in patient-
derived cells.
FLVCR1 is important for the survival of neuroblastoma cells
The identification of FLVCR1 mutations in patients with loss of pain perception, as well as
PCARP, indicate that FLVCR1 plays a critical role in the nervous system. Previous studies con-
firmed the expression of FLVCR1 in the mouse brain, retina and spinal cord[14]. We analyzed
FLVCR1a mRNA levels in different mouse tissues. FLVCR1a mRNA levels are higher in the
brain compared to other tissues characterized by elevated production of hemoproteins (S5
Fig). This data suggests that FLVCR1a mediated heme export is relevant for neurons.
We previously reported that FLVCR1a is essential to prevent heme-induced oxidative stress
in several cell types, including erythroid progenitors, hepatocytes and intestinal cells[21, 22,
33]. To get an insight into the role of FLVCR1a in neuronal cells, shRNA-mediated knock-
down experiments were performed in SH-SY5Y neuroblastoma cells (Fig 4A and S2 Fig).
Increased ROS levels were detected in FLVCR1a-downregulated SH-SY5Y cells compared to
controls (Fig 4B), thus indicating a conserved role for FLVCR1a in neuroblastoma cells. Next,
we investigated whether FLVCR1a is essential for the survival of these cells. Increased percent-
age of Annexin V-positive cells was detected in FLVCR1a-downregulated SH-SY5Y cells com-
pared to controls, both under resting conditions and following the stimulation with ALA (Fig
4C). Together, these data indicate that heme export through FLVCR1a is important for the
survival of neuronal cells.
Discussion
Different mechanisms leading to sensory neurodegeneration and pain loss have been
described. For example mutations in voltage-gated sodium channels, membrane-shaping pro-
teins or the autophagy receptor FAM134B, which triggers turnover of the endoplasmic reticu-
lum, are causative for sensory neuron loss[1, 5]. Altered sphingolipid metabolism, impaired
neurotrophin signaling or epigenetic dysregulation likewise results in sensory neuron damage
[34]. We here report patients with early-onset pain insensitivity because of mutations in the
heme exporter FLVCR1. The finding suggests that heme metabolism is critically involved in
sensory neuron maintenance.
The FLVCR1 gene is under strong positive selection with Residual Variation Intolerance
Score (RVIS) and Gene Damage Index (GDI) scores of 0.02 (55.45%) and 2854.439, respec-
tively. Thus, the genic intolerance is estimated to be rather average and when testing for selec-
tive pressure, the GDI is classified as “medium damage prediction”. As part of the Major-
Facilitator-Superfamily (MFS) FLVCR1 and other family members share 12 transmembrane
alpha helices connected by hydrophilic loops. The subRVIS-prediction tool indicates that the
crucial MFS domain of FLVCR1, in which all four mutations reported here are located, has a
low RVIS score of -1.39 (3.96%), indicating a strong negative selection for this particular
domain. This is compatible with pathogenicity of mutations residing in the conserved MFS
domain. In contrast, the less well conserved N- and C-terminal regions of FLVCR1 show
mean ± SEM. n = 6. Two-way ANOVA. *** = P<0.001. (E) Annexin V-positive cells in patient 2 compared to control LCLs under basal conditions
and following the stimulation with 5mM ALA for 72 hours. Values represent the percentage of Annexin V-positive cells of patient 2 LCLs
compared to the mean percentage of Annexin V-positive cells of 4 different control LCLs. (F) Annexin V-positive cells in patient LCLs grown in
starved medium, treated with 5mM ALA and with or without Hemopexin (HX) for 24 hours. Values represent mean ± SEM. n = 6. Two-way
ANOVA. *** = P<0.001. P1 = patient 1, P2 = patient 2, C = control.
doi:10.1371/journal.pgen.1006461.g003
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higher subRVIS scores of 0.07 (55.86%) and 1.12 (93.99%), respectively, which explains the
overall higher RVIS score of FLVCR1.
FLVCR1 is a heme exporter involved in the control of intracellular heme levels in different
cell types[20–25].
We demonstrated that sensory neuropathy-associated FLVCR1-mutations compromise the
ability of FLVCR1a to export heme. Patient-derived primary cells showed altered expression of
genes transcriptionally regulated by heme and accumulation of heme following the stimulation
of endogenous heme synthesis. Thus, we propose that reduced heme export activity may cause
heme accumulation and cellular damage by heme toxicity in sensory neurons.
The analysis of patient-derived cells also indicates that FLVCR1 impairment triggers com-
pensatory mechanisms to counteract the accumulation of heme. Indeed, increased heme deg-
radation was observed in patient fibroblasts whereas decreased heme synthesis rates were
found in patient LCLs. However, these mechanisms fail to completely protect the cells from
heme toxicity, especially under stress conditions, resulting in oxidative stress and increased
susceptibility to programmed cell death. These data are in agreement with previous studies
indicating an essential role for FLVCR1a to prevent heme-induced oxidative stress in different
cell types[21, 22].
We here show a conserved role for FLVCR1a in neuronal cells. Silencing of FLVCR1a
induces oxidative stress and affects the survival of neuroblastoma cells under resting condi-
tions, thus suggesting that neuronal cells are particularly sensitive to the loss of FLVCR1a. We
propose FLVCR1a as an important heme exporter in sensory neurons which regulates the oxi-
dative stress response.
Mutations in the human FLVCR1 gene were previously associated to Posterior Column
Ataxia and Retinitis Pigmentosa (PCARP)[12]. PCARP is a childhood-onset, autosomal-reces-
sive disorder with the clinical features of sensory ataxia and retinitis pigmentosa[11–14, 35].
Fig 4. FLVCR1a is important for the survival of neuroblastoma cells. (A) qRT-PCR analysis of FLVCR1a mRNA levels in FLVCR1a-
depleted SH-SY5Y cells compared to control (scramble). Values represent mean ± SEM. n = 3. ** = P<0.005. (B) Measurement of ROS
levels mRNA in FLVCR1a-downregulated SH-SY5Y cells compared to controls. Values represent mean ± SEM. n = 6. ** = P<0.005. (C)
Annexin V staining of FLVCR1a-downregulated SH-SY5Y cells compared to controls. Values represent mean ± SEM. n = 3. Two-way
ANOVA. * = P<0.05; ** = P<0.005.
doi:10.1371/journal.pgen.1006461.g004
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Interestingly, polyneuropathy has been reported in a patient affected by PCARP, however, not
as leading clinical manifestation but as additional symptom at a later state of disease[11]. In
the majority of patients affected by PCARP, homozygous missense mutations in the FLVCR1
gene have been reported[12]. These mutations affect highly conserved residues of FLVCR1
important for protein expression, localization, folding or regulation of heme efflux[12]. Both
patients reported here harbour a missense-mutation on one allele and a severe frameshift-
mutation on the other FLVCR1 alleles, the latter most likely resulting in a truncated FLVCR1a
protein that may be rapidly degraded, acts as a dominant negative molecule or leads to non-
sense-mediated mRNA decay (NMD). Such mutations are likely to cause severely impaired
heme efflux rates, which may be particularly relevant for sensory neurons. This finding sug-
gests that the type of mutation critically determines the phenotypic outcome of the disease.
It is well known that heme is involved in multiple biological processes[26], yet the role of
heme metabolism in the nervous system has been poorly addressed. The finding of FLVCR1
mutations in patients with peripheral sensory neuropathy suggests that heme metabolism via
FLVCR1a plays an essential role for maintenance of these specialized neurons. Heme is essen-
tial for ATP production through oxidative phosphorylation. Indeed, heme is the fundamental
cofactor of cytochromes of the electron transport chain[36–38] and reduced heme synthesis
cause a reduction of complex IV activity and ATP synthesis[39]. Peripheral nerves need effi-
cient energetic metabolism because of a considerable length of the axon. For this reason, sen-
sory neurons may be particularly sensitive to disturbances in heme homeostasis and
dependent on heme synthesis for oxidative phosphorylation, to sustain both anterograde and
retrograde trafficking along the extraordinarily long axonal processes. Interestingly, the nerve
growth factor signaling cascade (NGF/TrkA) is essential for sensory neuron survival and
mutations in both NGF and its receptor, TrkA, encoded by NTRK1, lead to sensory and auto-
nomic neuropathy. Since heme is known to regulate NGF signaling[40], it is tempting to spec-
ulate that altered NGF signaling provides a pathophysiological link to the FLVCR1 disorder.
Heme levels are also directly involved in neuron excitability and nociception by modulating
the activity of voltage-gated K+ channels. Voltage-gated K+ channels are a large family of K
+ channels that open on membrane depolarization and contribute to maintain the resting
potential and to determine the characteristics and frequency of action potentials[41]. Several
studies highlight a pivotal role of K+ channels in pain processing[42, 43]. Knocking-down spe-
cific K+ channels subunits results in alteration of nociception in mouse models[43].
Heme directly binds to the large-conductance calcium-dependent Slo1 BK channels and
Kv1.4 A-type K+ channels. The high affinity binding of heme to Slo1 decreases the frequency
of channel opening leading to an inhibition of transmembrane K+ currents[44, 45]. Its binding
to the N-terminal domain of Kv1.4 channels inhibits the fast inactivation of the channel, thus
reducing cellular excitability[46].
Heme can also indirectly modulate the activity of K+ channels through the production of
ROS and carbon monoxide. ROS modulation of K+ channel activity has already been reported
[41] and CO plays multiple roles in nociception[47]. Moreover, it has been proposed that oxi-
dative stress promotes the development of acquired forms of neuropathy, like diabetic neurop-
athy[48, 49] and chemotherapy-induced neuropathy[50, 51].
Taken together, our data emphasize a critical role of heme metabolism for homeostasis of
sensory neurons and suggest FLVCR1 as a neuroprotective target.
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Materials and Methods
Patients
Patients were recruited by the specialized outpatient services for Rare Diseases at the Gaslini
Hospital in Genova (Patient 1) and of Clinical/Medical Genetics at the San Camillo-Forlanini
Hospital in Rome (Patient 2), Italy. Both patients are of European origin, and from non-con-
sanguineous families. Patient 1 samples were obtained from the “Cell Line and DNA Biobank
from patients affected by Genetic Diseases” (Istituto Giannina Gaslini), member of Telethon
Network of Genetic Biobanks (project no. GTB12001). Patient 1 underwent peripheral blood
sampling for molecular testing, and skin punch biopsy for fibroblast culture and functional
studies. Patient 2 underwent peripheral blood sampling for molecular testing and lymphocyte
culture. Because of slow healing wounds the family dissented with skin biopsies. Both patients
were evaluated by full clinical and detailed instrumental investigations, comprising neurophys-
iological assessment, brain and total spine MRI.
As controls, we used primary fibroblasts and LCLs derived from healthy donors. Control
fibroblasts were obtained from the “Cell Line and DNA Biobank from patients affected by
Genetic Diseases” (Istituto Giannina Gaslini), member of Telethon Network of Genetic Bio-
banks (project no. GTB12001). As control, we chose primary fibroblasts derived from an indi-
vidual with comparable age to that of patient 1 (newborn child). Controls LCLs were derived
from healthy donors at the Molecular Biotechnology Center, University of Torino, Italy. Con-
trol and patient samples derived from individuals belonging to the same genetic population
(European origin).
The study was approved by the local ethics board of the University Hospital Jena (research
ethics approval 3244-09/11) and of the San Camillo Forlanini Hospital Rome (research ethics
approval OSR83/2016). Written consent for the study was obtained from the participants or
their legally authorized representatives. This research is in accordance with the Helsinki
Declaration.
Cell culture. Human neuroblastoma SH-SY5Y cell line (ATCC no. RL-2266) was propa-
gated in DMEM/F12 medium (TermoFisher Scientific) supplemented with 10% heat-inacti-
vated low-endotoxin fetal bovine serum (TermoFisher Scientific), 100 U/ml penicillin and 100
mg/ml streptomycin.
Control and patient-derived primary fibroblasts were propagated in RPMI 1640 medium
(TermoFisher Scientific) supplemented with 15% heat-inactivated low-endotoxin fetal bovine
serum (TermoFisher Scientific), 100 U/ml penicillin and 100 mg/ml streptomycin.
Control and patient-derived lymphoblastoid cell lines (LCLs) were propagated in RPMI
1640 medium (TermoFisher Scientific) supplemented with 20% heat-inactivated low-endo-
toxin fetal bovine serum (TermoFisher Scientific), 100 U/ml penicillin and 100 mg/ml
streptomycin.
Cells were maintained at 37˚C under a 5% CO2 atmosphere.
To stimulate the endogenous heme synthesis cells were treated with 5mM ALA (A3785;
Sigma-Aldrich).
To facilitate heme efflux through FLVCR1a, LCLs were stimulated with 5μM or 15μM
Hemopexin (CSL; Behring) under starved conditions.
FLVCR1a silencing. The downregulation of FLVCR1a in SH-SY5Y cells was achieved
using a specific shRNA, as previously reported[18]. Briefly, a shRNA against the first exon of
human FLVCR1 gene (Open Biosystem) was used to specifically down-regulate FLVCR1a
expression. A shRNA against a scramble (SCR) sequence was used as control. Following lenti-
viral infection, cells were selected with 0.02μg/ml puromycin.
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Whole-exome sequencing. For trio whole-exome sequencing, 50 ng of DNA from
patients and parents were tagmented (Illumina). The fragments were adaptor-ligated including
incorporation of sample index barcodes. Libraries were subjected to an enrichment process
(Nextera Rapid Capture Exome Kit, Illumina). Samples were sequenced on a NextSeq550 plat-
form. This resulted in 29 Gb of mapped sequences with a mean coverage of 250 and a 50x cov-
erage of approx. 90% and a 10x coverage of 99.3% of target sequences per individual.
Gene panel sequencing. HaloPlex libraries for NGS were prepared using the HaloPlex
Target Enrichment kit for custom design (1-500kb target region, Agilent Technologies)
according to the manufacturer’s protocols. Target sequences (exons) and adjacent intronic
(±50bp) sequences were enriched with the designed HaloPlex probes selected with Agilent’s
SureDesign software. The panel included known disease-causative genes for hereditary pain
disorders (genes implicated in HSAN1-HSAN8, or CIP) as well as functional candidate genes
(genes encoding TRP-channels, ASICs, neurotrophins and their receptors). Libraries were run
on a MiSeq Sequencer (Illumina) with a 300 cycle MiSeq reagent kit v2 (Illumina).
Processing of next-generation sequencing (NGS) data. Primary data were filtered
accordingly to signal purity with the Illumina Real-Time Analysis (RTA) software v1.8. Reads
were mapped against the human reference genome built 19 (hg19) using the Burrows-
Wheeler-Aligner tool (bwa). Paired end reads were fixed by PICARD. Several steps to enhance
data-quality were carried out using GATK v3.3, e.g. local realignment around short insertion
and deletions and recalibration of the base quality scores. The GATK HaplotypeCaller was
used to identify SNPs and INDELs. Subsequently, variant re-calibration was performed using
stochastic models and divers training-sets (hapmap_3.3.hg19, 1000G_omni2.5.hg19,
dbsnp_138.hg19,1000G_phase1.snps.high_confidence.hg19,Mills_and_1000G_gold_standard.
indels.hg19). Detected variants were then annotated with the help of ANNOVAR. Specific fil-
ter-criteria were applied: focus on exonic and splicing regions; allele frequency of less than
0.01 in dbSNP, the 1000-Genomes project, the Exome Variant Server or the ExAC browser
and in an in-house database; and prioritization for de novo mutations and compound-hetero-
zygous / homozygous variants.
Sanger sequencing. Sanger sequencing was performed using standard procedures. Auto-
mated electrophoreses was done on a capilary electrophoretic ABI 3130 genetic analyzer
(Applied Biosystems).
Immunoprecipitation and western blotting. Control and patient-derived fibroblasts and
LCLs were lysed in TBS1X;Triton1% supplemented with protease inhibitors (Roche). Cell
debris was removed by centrifugation at 13,000 g for 10 min and the supernatant was collected.
50μg of total protein extracts were used for western blotting. For immunoprecipitation, 1mg of
total protein extracts were immunoprecipitated with anti-FLVCR1 antibody (Abnova
H00028982-D01P). Anti-SUMO (Thermo Fisher Scientific 519100) antibody was used as
control.
Proteins were separated on 10% SDS–PAGE, transferred on nitrocellulose membrane and
incubated with antibodies specific for FLVCR1 (Abnova H00028982-D01P), HO1 (ENZO
ADI-SPA-896F), ALAS1 (Abcam ab84962) and β-actin (Sigma). Detection of immunoblots
was carried out with ECL (Biorad).
RNA extraction and quantitative real-time PCR analysis. Total RNA was extracted
using PureLink RNA Mini Kit (TermoFisher Scientific). For quantitative real-time PCR
(qRT-PCR), 1 μg total RNA was treated with DNAse (Promega) and transcribed into comple-
mentary DNA (cDNA) using High-Capacity cDNA Reverse Transcription Kit (TermoFisher
Scientific). qRT-PCR was performed on a 7300 Real Time PCR System (Applied Biosystems)
using Universal Probe Library System (Roche). See S3 and S4 Tables for details.
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Measurement of heme content. Intracellular heme concentration of control and patient-
derived cells, as well as SH-SY5Y cells, was measured using a fluorescence assay, as previously
reported[52]. Briefly, cells were collected and resuspended in 2 M oxalic acid and heated at
95˚C for 30 minutes, leading to iron removal from heme. The resultant protoporphyrin was
measured by fluorescence (400 nm excitation and 662 or 608 nm emission). Data were nor-
malized to the endogenous protoporphyrin content (by measuring the fluorescence of not-
heated samples) and to total protein concentration. Results were expressed as pmol of heme/
mg total protein
Measurement of intracellular ROS accumulation. Accumulation of reactive oxygen spe-
cies (ROS) in control and patient-derived cells, as well as SH-SY5Y cells, was assessed by using
the oxidant-sensitive fluorescent dye 29,79-dichlorodihydrofluoroscein diacetate (H2DCFDA;
Molecular Probes, Inc., Eugene, OR)[21, 33]. H2DCFDA penetrates easily into the cells. Upon
crossing the cellular membrane, H2DCFDA undergoes deacetylation by intracellular esterases
producing a nonfluorescent compound that becomes highly green fluorescent following oxida-
tion by intracellular reactive oxygen species. Within the cell, the probe reacts with ROS to
form fluorescent 28,78 dichlorofluoroscein (DCF), which is detected by fluorometry. Control
and patient-derived cells, as well as SH-SY5Y cells, were incubated with 5mM H2DCFDA in
Hanks’ balanced salt solution (HBSS) for 30 min at 37˚C under 5% CO2 atmosphere. atmo-
sphere. Then, cells were washed twice with 0.1 M PBS and lysed in 0.1 M PBS. A quantity of
lysate correspondent to 10 μg protein was analyzed. Fluorescence was recorded at excitation
and emission wavelengths of 485 and 530 respectively by a fluorimeter plate reader (Promega).
The background fluorescence caused by buffer and DCF was subtracted from the total fluores-
cence in each well generated by cells in presence of DCF.
Annexin V staining
Control and patient-derived cells, as well as SH-SY5Y cells, were collected, washed in PBS1X,
resuspended in 10 mM Hepes, 150 mM NaCl, 5 mM CaCl2 buffer, and labelled with Annex-
inV-FITC (BD Biosciences) for 15 minutes. Then, 2 μl propidium iodide (1 mg/ml) (PI;
Sigma-Aldrich) was added. AnnexinV emission was detected in the green channel (525 nm)
and propidium iodide in the red channel (575nm) on a FACS Calibur Cytometer (BD Biosci-
ences). For each sample, 10’000 to 25’000 events were collected.
Statistical analyses
Results were expressed as mean ± SEM. Statistical analyses were performed using one-way or
two-way analysis of variance or Student’s t test. A P value of less than 0.05 was considered
significant.
Supporting Information
S1 Fig. (A) Mild hyperintensity of the posterior columns at the cervical metameteres in
patient 2. (B) cervical syringomyelia in the same patient.
(TIF)
S2 Fig. (A) qRT-PCR analysis of FLVCR1b mRNA levels in patient 1 and control fibroblasts.
Values represent mean ± SEM. N = 6. (B) qRT-PCR analysis of FLVCR1b mRNA levels in
patient 2 and control LCLs. Values represent mean FLVCR1b mRNA levels compared to the
mean FLVCR1b mRNA levels of 4 different control LCLs. (C) qRT-PCR analysis of FLVCR1b
mRNA levels in FLVCR1a-downregulated SH-SY5Y cells compared to controls (scramble).
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Values represent mean ± SEM. N = 6.
(TIF)
S3 Fig. Densitometric analysis of HO1 and ALAS1 protein levels in patient 2 LCLs com-
pared to the mean protein levels of 4 different control LCLs.
(TIF)
S4 Fig. Annexin V-positive cells in patient 2 compared to control LCLs, under basal condi-
tions and following the stimulation with 5μM H2O2 for 72 hours. Values represent
mean ± SEM. n = 3.  = P<0.005;  = P<0.001.
(TIF)
S5 Fig. qRT-PCR analysis of FLVCR1a mRNA levels in different wild-type mouse tissues.
Values represent mean ± SEM. n = 5.  = P<0.005;  = P<0.001.
(TIF)
S1 Table. Whole-exome sequencing data. De novo variants as well as compound heterozy-
gous and homozygous variants are given for both trios.
(XLSX)
S2 Table. In silico prediction. Pathogenicity of FLVCR1 variants is predicted by several pre-
diction programs.
(XLSX)
S3 Table. Primers and probes used for qRT-PCR analyses. The primers and probes were
designed using the ProbeFinder Software (Roche). Human β-actin (TermoFisher Scientific)
was used as endogenous control.
(PDF)
S4 Table. Primers and probes used for qRT-PCR analyses. To discriminate between
FLVCR1a and FLVCR1b, specific primers and probes were designed using Primer Express
Software Version 3.0 (Applied Biosystems). Human β-actin (TermoFisher Scientific) was used
as endogenous control.
(PDF)
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